Arcadia Biosciences (NASDAQ:RKDA) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a report issued on Friday. The brokerage issued a sell rating on the basic materials company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 price objective on shares of Arcadia Biosciences in a research report on Wednesday, August 21st.

Arcadia Biosciences Price Performance

RKDA stock traded down $0.96 on Friday, hitting $2.90. 64,881 shares of the company were exchanged, compared to its average volume of 18,779. Arcadia Biosciences has a twelve month low of $1.85 and a twelve month high of $5.34. The business’s fifty day moving average is $3.34 and its two-hundred day moving average is $3.02. The stock has a market capitalization of $3.94 million, a price-to-earnings ratio of -0.68 and a beta of 1.27.

Arcadia Biosciences (NASDAQ:RKDA) last released its quarterly earnings data on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.27 by ($0.49). Arcadia Biosciences had a negative return on equity of 52.63% and a negative net margin of 110.61%. The business had revenue of $1.31 million during the quarter, compared to analyst estimates of $0.95 million. During the same period in the previous year, the company earned ($2.64) EPS. Equities research analysts expect that Arcadia Biosciences will post -1.7 earnings per share for the current year.

About Arcadia Biosciences

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.